Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025
Amicus Therapeutics, Inc. has become one of the most closely watched rare-disease stocks heading into the final stretch of 2025 after BioMarin Pharmaceutical announced…

















